Offsetting Liabilities [Line Items]
Offsetting Liabilities [Line Items]
Accumulated Amortization
Finite-Lived Intangible Assets, Accumulated Amortization
Statistical Measurement [Domain]
Statistical Measurement [Domain]
Other current assets
Other Current Assets [Member]
Award Timing Predetermined
Award Timing Predetermined [Flag]
Entity File Number
Entity File Number
Additional Paid-in Capital
Additional Paid-in Capital [Member]
Interest Rate Swap
Interest Rate Swap [Member]
Equity in loss of investees
Income (Loss) from Equity Method Investments
Tabular List, Table
Tabular List [Table Text Block]
Adoption of New Accounting Standards and Recent Accounting Pronouncements
New Accounting Pronouncements, Policy [Policy Text Block]
Rylaze/Enrylaze
Rylaze/Enrylaze [Member]
Rylaze/Enrylaze
Accounts payable
Increase (Decrease) in Accounts Payable
Interest expense, net
Interest Income (Expense), Nonoperating
Xyrem
Xyrem [Member]
Xyrem [Member]
Shares withheld for payment of employees' withholding tax liability
Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation
Gross Unrealized Losses
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Trading Arrangements, by Individual
Trading Arrangements, by Individual [Table]
Basic (in dollars per share)
Earnings Per Share, Basic
Adjustment to Compensation:
Adjustment to Compensation [Axis]
Named Executive Officers, Footnote
Named Executive Officers, Footnote [Text Block]
Liabilities:
Liabilities, Fair Value Disclosure [Abstract]
Revenues
Revenue from Contract with Customer [Text Block]
Gross Amounts Not Offset in the Consolidated Balance Sheet
Derivative Asset, Including Not Subject to Master Netting Arrangement, after Offset and Deduction [Abstract]
Inventory Disclosure [Abstract]
Inventory Disclosure [Abstract]
Clinical trial accruals
Accrued Clinical Trial Liability, Current
Accrued Clinical Trial Liability, Current
Issuance of ordinary shares in conjunction with vesting of restricted stock units and performance-based restricted stock units (in shares)
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures
Schedule of Cash, Cash Equivalents and Investments
Cash, Cash Equivalent, and Investment [Table Text Block]
Inventory-related accruals
Accrued Inventory Related Liabilities, Current
Accrued Inventory Related Liabilities, Current
FDA stay of approval period (in months)
FDA Stay Of Approval Period
FDA Stay Of Approval Period
Adjustment to Compensation, Amount
Adjustment to Compensation Amount
Percentage of total revenues (as a percent)
Concentration Risk, Percentage
Basis of Presentation
Consolidation, Policy [Policy Text Block]
Share-based compensation
Share-Based Payment Arrangement, Noncash Expense
Thereafter
Finite-Lived Intangible Asset, Expected Amortization, After Year Four
Finite-Lived Intangible Asset, Expected Amortization, After Year Four
Contractual coupon rate interest expense
Interest Expense, Debt, Contractual Coupon Rate
Interest Expense, Debt, Contractual Coupon Rate
Employee Stock Option
Share-Based Payment Arrangement, Option [Member]
Award Timing MNPI Disclosure
Award Timing MNPI Disclosure [Text Block]
Property, Plant and Equipment [Table]
Property, Plant and Equipment [Table]
Cash consideration
Proceeds from Sale of Productive Assets
Cash and Cash Equivalents
Cash and Cash Equivalents [Member]
Antidilutive Securities [Axis]
Antidilutive Securities [Axis]
Cash and Available-for-Sale Securities
Cash, Cash Equivalent, and Short-Term Investment [Text Block]
Tax (benefit) expense effect on cash flow hedging activities reclassified
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax
Total shareholders’ equity
Beginning balance
Ending balance
Equity, Attributable to Parent
Other comprehensive income (loss) before reclassifications
OCI, before Reclassifications, Net of Tax, Attributable to Parent
Debt Securities, Available-for-sale [Table]
Debt Securities, Available-for-Sale [Table]
Other comprehensive income (loss):
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Insider Trading Policies and Procedures [Line Items]
Total share-based compensation expense, pre-tax
Share-Based Payment Arrangement, Expense
Schedule of Property, Plant and Equipment
Property, Plant and Equipment [Table Text Block]
Hedging Designation [Domain]
Hedging Designation [Domain]
Fair value of secured debt
Notes Payable, Fair Value Disclosure
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Abstract]
Current assets:
Assets, Current [Abstract]
Total liabilities and shareholders’ equity
Liabilities and Equity
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Concentration Risk Benchmark [Axis]
Concentration Risk Benchmark [Axis]
LIABILITIES AND SHAREHOLDERS’ EQUITY
Liabilities and Equity [Abstract]
Percentage of post-tax proceeds entitled
Sale of Productive Asset, Percent Of Post-Tax Proceeds Entitled
Sale of Productive Asset, Percent Of Post-Tax Proceeds Entitled
Cover [Abstract]
Cover [Abstract]
Amounts reclassified from accumulated other comprehensive loss
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent
Maximum
Maximum [Member]
Total share-based compensation expense, net of tax
Share-Based Payment Arrangement, Expense, after Tax
Derivative Financial Instruments
Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Security Not Offset
Accounting Policies [Abstract]
Accounting Policies [Abstract]
Total
Finite-Lived Intangible Assets, Net
Concentration Risk Type [Domain]
Concentration Risk Type [Domain]
Repayments of long-term debt
Repayments of Secured Debt
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Total Compensation Amount
Debt Instrument [Line Items]
Debt Instrument [Line Items]
Epidiolex/Epidyolex
Epidiolex/Epidyolex [Member]
Epidiolex/Epidyolex
Adjustment to Non-PEO NEO Compensation Footnote
Adjustment to Non-PEO NEO Compensation Footnote [Text Block]
Pay vs Performance Disclosure [Line Items]
Tranche B 2 Dollar Term Loan
Tranche B 2 Dollar Term Loan [Member]
Tranche B 2 Dollar Term Loan
Share Repurchase Program [Line Items]
Share Repurchase Program [Line Items]
Foreign currency translation adjustments
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Non-Rule 10b5-1 Arrangement Terminated
Non-Rule 10b5-1 Arrangement Terminated [Flag]
Totals
Financial Liabilities Fair Value Disclosure
Entity Shell Company
Entity Shell Company
Other non-current liabilities
Other Liabilities, Noncurrent
Schedule of Long-term Debt Instruments [Table]
Schedule of Long-Term Debt Instruments [Table]
Loss Contingency Nature [Axis]
Loss Contingency Nature [Axis]
Statement of Stockholders' Equity [Abstract]
Statement of Stockholders' Equity [Abstract]
Inventory, step-up value
Inventory, Step-Up Value
Inventory, Step-Up Value
2026 Notes
Exchangeable Senior Notes Due 2026 [Member]
Exchangeable Senior Notes Due 2026 [Member]
Unrealized gain (loss) on cash flow hedging activities, net of income tax (benefit) expense of $— and $(0.1) respectively
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax
Statement of Cash Flows [Abstract]
Statement of Cash Flows [Abstract]
Current portion of long-term debt
Less current portion
Long-Term Debt, Current Maturities
Company Selected Measure Amount
Company Selected Measure Amount
Cash
Cash
Award Timing MNPI Considered
Award Timing MNPI Considered [Flag]
Total comprehensive income
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Name
Measure Name
Offsetting Liabilities [Table]
Offsetting Liabilities [Table]
Schedule of Share-Based Compensation Expense
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
Secured Notes
Secured Debt [Member]
Sleep
Sleep [Member]
Sleep
Deferred tax liabilities, net
Deferred Income Tax Liabilities, Net
Computer software
Software and Software Development Costs [Member]
Document Fiscal period Focus
Document Fiscal Period Focus
Derivatives, Fair Value [Line Items]
Derivatives, Fair Value [Line Items]
Award Timing Method
Award Timing Method [Text Block]
Litigation Case [Domain]
Litigation Case [Domain]
Furniture and fixtures
Furniture and Fixtures [Member]
Award Type [Axis]
Award Type [Axis]
Foreign Currency Translation Adjustments
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Methods of Treatment when Administered with other Medications
Methods Of Treatment When Administered With Other Medications [Member]
Methods Of Treatment When Administered With Other Medications
Total debt
Long-Term Debt
Total assets
Assets
Jazz Investments I Limited
Jazz Investments I Limited [Member]
Jazz Investments I Limited [Member]
2027
Finite-Lived Intangible Asset, Expected Amortization, Year One
Trading Symbol
Trading Symbol
Geographical [Domain]
Geographical [Domain]
Entity Address, City or Town
Entity Address, City or Town
Operating activities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]
Remaining Weighted- Average Useful Life (In years)
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life
Effect of exchange rates on cash and cash equivalents
Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Concentration Risk Type [Axis]
Concentration Risk Type [Axis]
Inventories
Inventory Disclosure [Text Block]
Non-PEO NEO Average Compensation Actually Paid Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Income Statement Location [Domain]
Statement of Income Location, Balance [Domain]
Compensation Actually Paid vs. Other Measure
Compensation Actually Paid vs. Other Measure [Text Block]
Assets:
Assets, Fair Value Disclosure [Abstract]
Cost of product sales (excluding amortization of acquired developed technologies)
Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment
Total costs related to goods produced and sold during the reporting period excluding amortization of acquired developed technologies and intangible asset impairment presented separately.
2030
Finite-Lived Intangible Asset, Expected Amortization, Year Four
Emerging Growth Company
Entity Emerging Growth Company
2029
Long-Term Debt, Maturity, Year Three
Research and development
Research and Development Expense (Excluding Acquired in Process Cost)
Acquisition of intangible assets
Payments to Acquire Intangible Assets
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Net income (loss) per ordinary share:
Net Income Loss Per Ordinary Share [Abstract]
Net Income Loss Per Ordinary Share
Cash Collateral Received (Pledged)
Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-Sale [Line Items]
Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year
Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]
Debt issuance costs
Debt Issuance Costs, Net
Significant Other Observable Inputs (Level 2)
Fair Value, Inputs, Level 2 [Member]
Gain (loss) recognized in foreign exchange gain (loss)
Derivative, Gain (Loss) on Derivative, Net
Insider Trading Policies and Procedures Not Adopted
Insider Trading Policies and Procedures Not Adopted [Text Block]
Business Combination [Domain]
Business Combination [Domain]
Beginning balance (in shares)
Ending balance (in shares)
Common Stock, Shares, Outstanding
Gain on sale of priority review voucher
Gain on sale of priority review voucher
Gain (Loss) on Disposition of Other Assets
FDA recognition of orphan drug exclusivity, period (in years)
FDA Recognition Of Orphan Drug Exclusivity, Period
FDA Recognition Of Orphan Drug Exclusivity, Period
PEO
PEO [Member]
Schedule of Disaggregation of Revenue
Disaggregation of Revenue [Table Text Block]
Proceeds from maturity of investments
Proceeds from Sale, Maturity and Collection of Investments
Interest income from available-for-sale securities
Investment Income, Interest
Income (loss) before income tax expense (benefit) and equity in loss of investees
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest
U.S.
UNITED STATES
Changes in assets and liabilities:
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]
Issuance of ordinary shares in conjunction with exercise of share options
Stock Issued During Period, Value, Stock Options Exercised
Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year
Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]
Schedule of Estimated Future Amortization Expenses
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Retained Earnings
Retained Earnings [Member]
Effective interest rate (as a percent)
Debt Instrument, Interest Rate, Effective Percentage
Schedule of Accrued Liabilities
Schedule of Accrued Liabilities [Table Text Block]
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Restatement Determination Date
Restatement Determination Date
Share-based Payment Arrangement [Abstract]
Share-Based Payment Arrangement [Abstract]
Cash and cash equivalents, at beginning of period
Cash and cash equivalents, at end of period
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Income Statement [Abstract]
Income Statement [Abstract]
Derivative assets
Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet
Derivative Asset
Income tax expense (benefit)
Income Tax Expense (Benefit)
Income tax (benefit) expense effect on cash flow hedging activities
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax
Income taxes payable
Taxes Payable, Current
Intangible assets, net
Intangible Assets, Net (Excluding Goodwill)
Pension Adjustments Service Cost
Pension Adjustments Service Cost [Member]
Derivatives designated as hedging instruments
Designated as Hedging Instrument [Member]
Xywav
Xywav [Member]
Xywav
Product and Service [Domain]
Product and Service [Domain]
Customer concentration risk
Customer Concentration Risk [Member]
Available-for-sale securities:
Debt Securities, Available-for-Sale [Abstract]
Fair Value Hierarchy and NAV [Axis]
Fair Value Hierarchy and NAV [Axis]
Estimated Fair Value
Cash, Cash Equivalents, and Short-Term Investments
Restatement does not require Recovery
Restatement Does Not Require Recovery [Text Block]
Notional amount
Derivative, Notional Amount
Payments related to sale of priority review voucher
Payments to Acquire Other Productive Assets
Sales return reserve
Sales Return Reserve, Current
Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales returns reserve. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Compensation Actually Paid vs. Company Selected Measure
Compensation Actually Paid vs. Company Selected Measure [Text Block]
Less accumulated depreciation and amortization
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization
City Area Code
City Area Code
Disposition
Mergers, Acquisitions and Dispositions Disclosures [Text Block]
Award Timing, How MNPI Considered
Award Timing, How MNPI Considered [Text Block]
All Trading Arrangements
All Trading Arrangements [Member]
Equity Awards Adjustments, Footnote
Equity Awards Adjustments, Footnote [Text Block]
Total Shareholder Return Vs Peer Group
Total Shareholder Return Vs Peer Group [Text Block]
Accrued liabilities
Total accrued liabilities
Accrued Liabilities, Current
Epilepsy
Epilepsy [Member]
Epilepsy
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Abstract]
Investing activities
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]
Pay vs Performance Disclosure
Pay vs Performance Disclosure [Table]
Net cash provided by operating activities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Selling, general and administrative
Selling, General and Administrative Expenses [Member]
Cost of product sales
Cost of Sales [Member]
Goodwill
Goodwill, beginning of period
Goodwill, end of period
Goodwill
Equity Valuation Assumption Difference, Footnote
Equity Valuation Assumption Difference, Footnote [Text Block]
PEO Total Compensation Amount
PEO Total Compensation Amount
Long-term Debt, Type [Axis]
Long-Term Debt, Type [Axis]
Depreciation
Depreciation
Pro Forma
Pro Forma [Member]
Money market funds
Money market funds
Money Market Funds [Member]
Performance-Based Restricted Stock Units (PRSUs)
Performance-Based Restricted Stock Units (RSUs) [Member]
Performance-Based Restricted Stock Units (RSUs)
2026 (remainder)
Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
Gross Amounts of Recognized Assets/ Liabilities
Derivative Liability, Subject to Master Netting Arrangement, before Offset
Equity Components [Axis]
Equity Components [Axis]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment [Line Items]
Convertible Debt
Convertible Debt
Convertible Debt [Member]
Non-Rule 10b5-1 Arrangement Adopted
Non-Rule 10b5-1 Arrangement Adopted [Flag]
Concentration Risk [Table]
Concentration Risk [Table]
The Company and Summary of Significant Accounting Policies
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]
Amortized Cost
Debt Securities, Available-for-Sale, Amortized Cost
Entity Address, Country
Entity Address, Country
Other Performance Measure, Amount
Other Performance Measure, Amount
Inventory [Line Items]
Inventory [Line Items]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Antidilutive Security, Excluded EPS Calculation [Table]
Total current liabilities
Liabilities, Current
All other
Other Countries [Member]
Other Countries [Member]
Derivative Instrument [Axis]
Derivative Instrument [Axis]
Individual:
Individual [Axis]
Property, plant and equipment, gross
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization
Net income (loss) per ordinary share:
Earnings Per Share Reconciliation [Abstract]
Rebates and other sales deductions
Accrued Rebates And Other Sales Deductions, Current
Carrying value as of the balance sheet date of obligations incurred through that date and payable for rebates and other sales deductions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Other current assets
Other Assets, Current
Research and development
Research and Development Expense [Member]
Additional paid-in capital
Additional Paid in Capital, Common Stock
Non-voting euro deferred shares
Nonvoting Euro Deferred Shares
Shares issued to satisfy statutory minimum of Euro-denominated share capital required for a public limited company incorporated in Ireland.
Selling and marketing accruals
Accrued Marketing Costs, Current
Net cash provided by (used in) investing activities
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table
Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]
Document Fiscal Year Focus
Document Fiscal Year Focus
Operating lease assets
Operating Lease, Right-of-Use Asset
Forgone Recovery, Explanation of Impracticability
Forgone Recovery, Explanation of Impracticability [Text Block]
Employee compensation and benefits
Accrued Employee Benefits, Current
Entity Interactive Data Current
Entity Interactive Data Current
Zepzelca
Zepzelca [Member]
Zepzelca
Loss Contingency, Nature [Domain]
Loss Contingency, Nature [Domain]
Number of patents, paragraph IV certification notice filed
Number Of Patents, Paragraph IV Certification Notice Filed
Number Of Patents, Paragraph IV Certification Notice Filed
Issuance of ordinary shares in conjunction with exercise of share options (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Summary of Deferred Revenue [Table]
Summary Of Deferred Revenue [Table]
Summary Of Deferred Revenue [Table]
Disaggregation of Revenue [Table]
Disaggregation of Revenue [Table]
Derivatives not designated as hedging instruments
Not Designated as Hedging Instrument [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trademarks
Trademarks [Member]
Long-Lived Tangible Asset [Axis]
Long-Lived Tangible Asset [Axis]
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets [Line Items]
Ownership [Domain]
Ownership [Domain]
Oncology
Oncology [Member]
Oncology
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Total Shareholder Return [Text Block]
Fair Value, Recurring and Nonrecurring [Table]
Fair Value, Recurring and Nonrecurring [Table]
Intangible asset amortization
Intangible asset amortization
Amortization of Intangible Assets
Teva Lawsuit
Teva Lawsuit [Member]
Teva Lawsuit
Selling, general and administrative
Selling, General and Administrative Expense
Deferred tax assets, net
Deferred Income Tax Assets, Net
Schedule of Components of Accumulated Other Comprehensive Loss
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]
Other non-current assets
Other Assets, Noncurrent
Customer [Domain]
Customer [Domain]
Accrued interest
Interest Payable, Current
Accrued royalties
Accrued Royalties, Current
Entity Central Index Key
Entity Central Index Key
PEO Name
PEO Name
Average market price of our ordinary shares exceed the conversion price (in dollars per share)
Debt Instrument, Convertible, Conversion Price
Schedule of Maturities of Long-Term Debt
Schedule of Maturities of Long-Term Debt [Table Text Block]
Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year
Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Dilutive effect of the Exchangeable Senior Notes (in shares)
Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
Outstanding Aggregate Erroneous Compensation Amount
Outstanding Aggregate Erroneous Compensation Amount
Amortized Cost
Cash, Cash Equivalents, and Short-Term Investments, Amortized Cost
Cash, Cash Equivalents, and Short-Term Investments, Amortized Cost
Arrangement Duration
Trading Arrangement Duration
ESSDS
Express Scripts [Member]
Express Scripts 1 [Member]
Computer equipment
Computer Equipment [Member]
Schedule of Fair Value of Outstanding Derivatives
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]
Prepaid expenses and other assets
Increase (Decrease) in Prepaid Expense and Other Assets
Work in process
Inventory, Work in Process, Net of Reserves
Exercise Price
Award Exercise Price
Entity Filer Category
Entity Filer Category
Local Phone Number
Local Phone Number
Additional 402(v) Disclosure
Additional 402(v) Disclosure [Text Block]
Europe
Europe [Member]
Inventory, Current [Table]
Inventory, Current [Table]
Share-Based Compensation
Share-Based Payment Arrangement [Text Block]
ASSETS
Assets [Abstract]
Long-term debt, less current portion
Total long-term debt
Long-Term Debt, Excluding Current Maturities
Underlying Security Market Price Change
Underlying Security Market Price Change, Percent
2029
Finite-Lived Intangible Asset, Expected Amortization, Year Three
Balance Sheet Location [Axis]
Statement of Financial Position Location, Balance [Axis]
Gross Amounts Not Offset in the Consolidated Balance Sheet
Derivative Liability, Including Not Subject to Master Netting Arrangement, after Offset and Deduction [Abstract]
Debt Instrument [Axis]
Debt Instrument [Axis]
Fair Value Measurement
Fair Value Disclosures [Text Block]
Time deposits
Time deposits
Bank Time Deposits [Member]
Gross Carrying Amount
Finite-Lived Intangible Assets, Gross
Shareholders’ equity:
Equity, Attributable to Parent [Abstract]
July 2024 Share Repurchase Program
July 2024 Share Repurchase Program [Member]
July 2024 Share Repurchase Program
Derivative instrument liabilities
Derivative Liability, Current
Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year
Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]
Entity Address, Address Line One
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Two
Defitelio/defibrotide
Defitelio/Defibrotide [Member]
Defitelio/Defibrotide [Member]
Accumulated Other Comprehensive Loss
Total Accumulated Other Comprehensive Loss
AOCI Attributable to Parent [Member]
Interest rate (as a percentage)
Debt Instrument, Interest Rate, Stated Percentage
Operating lease liabilities, less current portion
Operating Lease, Liability, Noncurrent
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]
Ownership [Axis]
Ownership [Axis]
Other
Other Products [Member]
Other Products [Member]
Derivative Instruments and Hedging Activities
Derivative Instruments and Hedging Activities Disclosure [Text Block]
Gross Amounts of Recognized Assets/ Liabilities
Derivative Asset, Subject to Master Netting Arrangement, before Offset
Fair Value as of Grant Date
Award Grant Date Fair Value
Entity Registrant Name
Entity Registrant Name
Stock Price or TSR Estimation Method
Stock Price or TSR Estimation Method [Text Block]
Ziihera
Ziihera [Member]
Ziihera
Schedule of Carrying Amount of Indebtedness
Schedule of Long-Term Debt Instruments [Table Text Block]
Dilutive effect of employee equity incentive and purchase plans (in shares)
Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements
Acquisition of investments
Payments to Acquire Investments
Total operating expenses
Costs and Expenses
Summary of Deferred Revenue [Line Items]
Summary Of Deferred Revenue [Line Items]
[Line Items] for Summary Of Deferred Revenue [Table]
Document Quarterly Report
Document Quarterly Report
Totals
Assets, Fair Value Disclosure
Changed Peer Group, Footnote
Changed Peer Group, Footnote [Text Block]
Equity securities without readily determinable fair value
Equity Securities without Readily Determinable Fair Value, Amount
Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]
Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]
Number of operating business segments
Number of Operating Segments
Adjustment To PEO Compensation, Footnote
Adjustment To PEO Compensation, Footnote [Text Block]
Non-voting Euro Deferred
Euro Deferred Shares [Member]
Euro Deferred Shares [Member]
Manufacturing equipment and machinery
Machinery and Equipment [Member]
Investments
Investments
Title
Trading Arrangement, Individual Title
Peer Group Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Schedule of Gross Carrying Amounts and Net Book Values of Intangible Assets
Schedule of Finite-Lived Intangible Assets [Table Text Block]
Restatement Determination Date:
Restatement Determination Date [Axis]
Non-PEO NEO
Non-PEO NEO [Member]
Accounts Receivable
Accounts Receivable [Member]
Accumulated Other Comprehensive Income (Loss) [Table]
Accumulated Other Comprehensive Income (Loss) [Table]
Interest expense, debt
Interest Expense, Debt
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Gross Unrealized Gains
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Schedule of Offsetting Assets
Offsetting Assets [Table Text Block]
Name
Trading Arrangement, Individual Name
Award Type [Domain]
Award Type [Domain]
Equity Awards Adjustments
Equity Awards Adjustments [Member]
Leasehold improvements
Leasehold Improvements [Member]
Other non-cash transactions
Other Noncash Income (Expense)
Pension Benefits Adjustments, Footnote
Pension Benefits Adjustments, Footnote [Text Block]
Disaggregation of Revenue [Line Items]
Disaggregation of Revenue [Line Items]
Compensation Amount
Outstanding Recovery Compensation Amount
Debt Instrument, Name [Domain]
Debt Instrument, Name [Domain]
Statement of Comprehensive Income [Abstract]
Statement of Comprehensive Income [Abstract]
Neena M. Patil [Member]
Neena M. Patil
Recovery of Erroneously Awarded Compensation Disclosure [Line Items]
Offsetting Assets [Table]
Offsetting Assets [Table]
Share Repurchase Program [Axis]
Share Repurchase Program [Axis]
Infringed patents suit, number of patents
Loss Contingency, Patents Allegedly Infringed, Number
Provision for losses on accounts receivable and inventory
Provision For Losses On Accounts Receivable And Inventory
Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction off the carrying amount of inventory, generally attributable to obsolescence or market conditions.
Acquisition accounting inventory fair value step-up adjustment
Inventory Step-Up Value Adjustment
The noncash expense recognized in the current period from the amortization of acquired inventory written up to fair value in purchase accounting
MNPI Disclosure Timed for Compensation Value
MNPI Disclosure Timed for Compensation Value [Flag]
Name
Awards Close in Time to MNPI Disclosures, Individual Name
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Current portion of lease liabilities
Operating And Finance Lease, Liability, Current
Operating And Finance Lease, Liability, Current
Aggregate Erroneous Compensation Not Yet Determined
Aggregate Erroneous Compensation Not Yet Determined [Text Block]
Payment terms, range (in days)
Revenue, Performance Obligation, Payment Terms
Revenue, Performance Obligation, Payment Terms
Revenues:
Revenues [Abstract]
Schedule of Percentage of Total Revenues from Customers
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]
Share-based compensation
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
Accumulated other comprehensive loss
Accumulated Other Comprehensive Income (Loss), Net of Tax
High-sodium oxybate AG royalty revenue
High Sodium AG Oxybate Product Royalty Revenue [Member]
High Sodium AG Oxybate Product Royalty Revenue
Country Region
Country Region
2027
Long-Term Debt, Maturity, Year One
Financial Instruments [Domain]
Financial Instruments [Domain]
Litigation Case [Axis]
Litigation Case [Axis]
Income Statement Location [Axis]
Statement of Income Location, Balance [Axis]
Aggregate Pension Adjustments Service Cost
Aggregate Pension Adjustments Service Cost [Member]
Fair Value Hierarchy and NAV [Domain]
Fair Value Hierarchy and NAV [Domain]
Loss (gain) on cash flow hedging activities reclassified from accumulated other comprehensive loss to interest expense, net of income tax (benefit) expense of $(0.1) and $0.1 respectively
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax
Balance Sheet Location [Domain]
Statement of Financial Position Location, Balance [Domain]
Inventories
Increase (Decrease) in Inventories
Inventories
Total inventories
Inventory, Net
Acquired developed technologies
Developed Technology Rights [Member]
Finite-Lived Intangible Assets by Major Class [Axis]
Finite-Lived Intangible Assets by Major Class [Axis]
Minimum
Minimum [Member]
Derivative Asset [Abstract]
Derivative Asset [Abstract]
Cash Collateral Received (Pledged)
Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset
Company Selected Measure Name
Company Selected Measure Name
Xywav and Xyrem
Xywav And Xyrem [Member]
Xywav And Xyrem
Gross Amounts Offset in the Consolidated Balance Sheet
Derivative Liability, Subject to Master Netting Arrangement, Asset Offset
Aggregate Available
Trading Arrangement, Securities Aggregate Available Amount
Accounts payable
Accounts Payable, Current
Stock Appreciation Rights (SARs)
Stock Appreciation Rights (SARs) [Member]
All Executive Categories
All Executive Categories [Member]
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note [Abstract]
Finished goods
Inventory, Finished Goods, Net of Reserves
Ordinary shares
Common Stock, Value, Issued
Goodwill [Roll Forward]
Goodwill [Roll Forward]
Modeyso
Modeyso [Member]
Modeyso
Commitments and Contingencies
Commitments and Contingencies Disclosure [Text Block]
Weighted-average ordinary shares used in per share calculations - diluted (in shares)
Weighted-average ordinary shares used in per share calculations - diluted (in shares)
Weighted Average Number of Shares Outstanding, Diluted
Commitments and contingencies (Note 10)
Commitments and Contingencies
Non-GAAP Measure Description
Non-GAAP Measure Description [Text Block]
Derivative [Table]
Derivative [Table]
Business Combination [Axis]
Business Combination [Axis]
Smaller Reporting Company
Entity Small Business
Irrevocable election for settlement method fix, maximum cash per $1,000 principal amount
Debt Instrument, Irrevocable Election For Settlement Method Fix, Maximum Cash Per $1,000 Principal Amount
Debt Instrument, Irrevocable Election For Settlement Method Fix, Maximum Cash Per $1,000 Principal Amount
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Abstract]
Accrued construction-in-progress
Accrued Construction-In-Progress, Current
Carrying value as of the balance sheet date of obligations incurred through that date and payable for construction-in-progress. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Debt
Long-Term Debt [Text Block]
Product sales, net
Product sales, net
Product And Services, Product Sales Net Of Deductions [Member]
Product And Services, Product Sales Net Of Deductions [Member]
Document Transition Report
Document Transition Report
Schedule of Percentage of Trade Receivables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]
Underlying Securities
Award Underlying Securities Amount
Concentration Risk [Line Items]
Concentration Risk [Line Items]
Equity Component [Domain]
Equity Component [Domain]
Document Period End Date
Document Period End Date
PEO Actually Paid Compensation Amount
PEO Actually Paid Compensation Amount
Income Taxes
Income Tax Disclosure [Text Block]
Certain Balance Sheet Items
Supplemental Balance Sheet Disclosures [Text Block]
General Composition and Method of Use
General Composition And Method Of Use [Member]
General Composition And Method Of Use
Awards Close in Time to MNPI Disclosures, Table
Awards Close in Time to MNPI Disclosures [Table Text Block]
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Abstract]
Hedging Designation [Axis]
Hedging Designation [Axis]
Net Amount
Derivative Asset, Including Not Subject to Master Netting Arrangement, after Offset and Deduction
Scenario [Axis]
Scenario [Axis]
Fair value of exchangeable senior notes
Convertible Debt, Fair Value Disclosures
Document Type
Document Type
Net Income (Loss) per Ordinary Share
Earnings Per Share [Text Block]
Name
Outstanding Recovery, Individual Name
Loss Contingencies [Table]
Loss Contingencies [Table]
Net Amount
Derivative Liability, Including Not Subject to Master Netting Arrangement, after Offset and Deduction
Product and Service [Axis]
Product and Service [Axis]
Derivative Contract [Domain]
Derivative Contract [Domain]
Total Revenues
Revenue from Contract with Customer Benchmark [Member]
Total revenues
Revenue from Contract with Customer, Excluding Assessed Tax
All Individuals
All Individuals [Member]
Long-term Debt, Type [Domain]
Long-Term Debt, Type [Domain]
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Abstract]
Purchases of property, plant and equipment
Payments to Acquire Property, Plant, and Equipment
Numerator:
Numerator [Abstract]
Numerator [Abstract]
Lupin Lawsuit
Lupin Lawsuit [Member]
Lupin Lawsuit
Name
Forgone Recovery, Individual Name
Infringed patents suit, number of patents
Infringed Patents Suit, Number Of Patents
Infringed Patents Suit, Number Of Patents
Total current assets
Assets, Current
Statistical Measurement [Axis]
Statistical Measurement [Axis]
Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested
Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]
Total amount authorized for repurchase of shares under share repurchase program
Share Repurchase Program, Authorized, Amount
Proceeds from employee equity incentive and purchase plans
Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised
Accrued liabilities
Accrued Liabilities [Member]
2030 Notes
2030 Notes
Exchangeable Senior Notes Due 2030 [Member]
Exchangeable Senior Notes Due 2030
Number of lawsuits filed
Loss Contingency, New Claims Filed, Number
Certain Balance Sheet Items [Abstract]
Certain Balance Sheet Items [Abstract]
Certain Balance Sheet Items [Abstract]
Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Amount
Foreign exchange
Goodwill, Foreign Currency Translation, Gain (Loss)
Payment of employee withholding taxes related to share-based awards
Payment, Tax Withholding, Share-Based Payment Arrangement
Peer Group Issuers, Footnote
Peer Group Issuers, Footnote [Text Block]
Derivatives, maximum contract term
Derivative, Term of Contract
Erroneous Compensation Analysis
Erroneous Compensation Analysis [Text Block]
Share Repurchase Program [Domain]
Share Repurchase Program [Domain]
Schedule of Finite-Lived Intangible Assets [Table]
Intangible Asset, Finite-Lived [Table]
Other comprehensive income (loss)
Other comprehensive loss (income)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Current liabilities:
Liabilities, Current [Abstract]
Geographical [Axis]
Geographical [Axis]
Derivative Liability [Abstract]
Derivative Liability [Abstract]
Schedule of Foreign Exchange Gain (Loss) Associated with Foreign Exchange Contracts Not Designated as Hedging Instruments
Derivative Instruments, Gain (Loss) [Table Text Block]
Rule 10b5-1 Arrangement Terminated
Rule 10b5-1 Arrangement Terminated [Flag]
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Inputs, Level 1 [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Foreign exchange gain (loss)
Gain (Loss), Foreign Currency Transaction, before Tax
Accrued liabilities
Increase (Decrease) in Accrued Liabilities
Diluted (in dollars per share)
Diluted (in dollars per share)
Earnings Per Share, Diluted
Tris Pharma Patent Litigation
Tris Pharma Patent Litigation [Member]
Tris Pharma Patent Litigation
Erroneously Awarded Compensation Recovery
Erroneously Awarded Compensation Recovery [Table]
Accounts receivable, net of allowances
Accounts Receivable, after Allowance for Credit Loss, Current
Concentration Risk Benchmark [Domain]
Concentration Risk Benchmark [Domain]
Title of 12(b) Security
Title of 12(b) Security
Capital Redemption Reserve
Capital Redemption Reserve [Member]
Capital Redemption Reserve [Member]
Scheduled Long-Term Debt Maturities
Long-Term Debt, Fiscal Year Maturity [Abstract]
Earnings Per Share [Abstract]
Earnings Per Share [Abstract]
Percentage of ownership (as a percent)
Subsidiary, Ownership Percentage, Parent
Derivative Liability, Statement of Financial Position [Extensible Enumeration]
Derivative Liability, Statement of Financial Position [Extensible Enumeration]
Investments, Debt and Equity Securities [Abstract]
Investments, Debt and Equity Securities [Abstract]
Non-cash interest expense
Noncash Interest Expense
Noncash Interest Expense
Schedule of Weighted-Average Ordinary Shares Excluded from Computation of Diluted Net Income (Loss) Per Share
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Stock repurchased
Stock Repurchased and Retired During Period, Value
GW Pharmaceuticals plc
GW Pharmaceuticals plc [Member]
GW Pharmaceuticals plc
Fair value of lines of credit
Lines of Credit, Fair Value Disclosure
Term Loan
Term Loan [Member]
Term Loan [Member]
Secured Notes
2029 Secured Notes [Member]
2029 Secured Notes
2028
Finite-Lived Intangible Asset, Expected Amortization, Year Two
Award Timing Disclosures [Line Items]
Schedule of Components of Inventories
Schedule of Inventory, Current [Table Text Block]
Long term debt outstanding
Total
Long-Term Debt, Gross
Manufacturing contracts
Manufacturing Contracts [Member]
Manufacturing Contracts [Member]
Property, plant and equipment, net
Property, plant and equipment, net
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization
Shareholders' Equity
Equity [Text Block]
Net income (loss)
Net income (loss)
Net income (loss)
Net Income (Loss) Attributable to Parent
Expiration Date
Trading Arrangement Expiration Date
Construction-in-progress
Construction in Progress [Member]
Other liabilities
Increase (Decrease) in Other Operating Liabilities
Other
Other Accrued Liabilities, Current
Vyxeos
Vyxeos [Member]
Vyxeos [Member]
Investments
Investments [Member]
Adoption Date
Trading Arrangement Adoption Date
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Net Income [Text Block]
Accounts receivable
Increase (Decrease) in Accounts Receivable
Entity Current Reporting Status
Entity Current Reporting Status
Derivative [Line Items]
Derivative [Line Items]
Customer [Axis]
Customer [Axis]
Awards Close in Time to MNPI Disclosures
Awards Close in Time to MNPI Disclosures [Table]
Income (loss) from operations
Operating Income (Loss)
Schedule of Offsetting Liabilities
Offsetting Liabilities [Table Text Block]
Capital redemption reserve
Capital Redemption Reserve
Capital redemption reserve created under Irish company law to preserve permanent capital in the company.
Retained earnings
Retained Earnings (Accumulated Deficit)
Mark D. Smith [Member]
Mark D. Smith
Liability derivatives
Derivative Liability, Gross Liability Including Not Subject to Master Netting Arrangement
Financial Instrument [Axis]
Financial Instrument [Axis]
Employee equity incentive and purchase plans
Equity Unit Purchase Agreements [Member]
Statement of Financial Position [Abstract]
Statement of Financial Position [Abstract]
Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested
Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]
Executive Category:
Executive Category [Axis]
Foreign exchange forward contracts
Foreign Exchange Forward [Member]
Ordinary Options
Ordinary Shares [Member]
Ordinary Shares [Member]
Current Fiscal Year End Date
Current Fiscal Year End Date
Net Unrealized Loss From Hedging Activities
Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]
Finite-Lived Intangible Assets, Major Class Name [Domain]
Finite-Lived Intangible Assets, Major Class Name [Domain]
Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table
Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]
Statement [Table]
Statement [Table]
Derivative liability
Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet
Derivative Liability
Deferred tax benefit
Deferred Income Tax Expense (Benefit)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]
Financing activities
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]
Equity Awards Adjustments, Excluding Value Reported in Compensation Table
Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]
Interest rate contracts
Interest Rate Contract [Member]
Defitelio Patent Litigation
Defitelio Patent Litigation [Member]
Defitelio Patent Litigation
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
Ordinary shares (in shares)
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
All Adjustments to Compensation
All Adjustments to Compensation [Member]
Fair Value, by Balance Sheet Grouping [Table]
Fair Value, by Balance Sheet Grouping [Table]
Amendment Flag
Amendment Flag
Income tax benefit from share-based compensation expense
Share-Based Payment Arrangement, Expense, Tax Benefit
2028
Long-Term Debt, Maturity, Year Two
Termination Date
Trading Arrangement Termination Date
Net cash used in financing activities
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Deferred financing costs
Debt Issuance Costs, Noncurrent, Net
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Adopted [Flag]
Denominator:
Denominator [Abstract]
Denominator [Abstract]
Measure:
Measure [Axis]
Raw materials
Inventory, Raw Materials, Net of Reserves
Long-Lived Tangible Asset [Domain]
Long-Lived Tangible Asset [Domain]
Weighted-average ordinary shares used in per share calculations - basic (in shares)
Weighted-average ordinary shares used in per share calculations - basic (in shares)
Weighted Average Number of Shares Outstanding, Basic
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Remaining amount authorized for repurchase of shares
Share Repurchase Program, Remaining Authorized, Amount
Land and buildings
Land and Building [Member]
Schedule of Basic and Diluted Net Income (Loss) Per Ordinary Share Computation
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
Share Repurchase Program [Table]
Share Repurchase Program [Table]
Asset derivatives
Derivative Asset, Gross Asset Including Not Subject to Master Netting Arrangement
Pay vs Performance Disclosure, Table
Pay vs Performance [Table Text Block]
Debt Disclosure [Abstract]
Debt Disclosure [Abstract]
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Amortization of debt issuance costs
Amortization of Debt Issuance Costs
Royalties and contract revenues
Product And Services, Royalties And Contract Revenue [Member]
Product And Services, Royalties And Contract Revenue [Member]
Entity Tax Identification Number
Entity Tax Identification Number
Scenario [Domain]
Scenario [Domain]
Other royalty and contract revenues
Other Royalty And Contract Revenues [Member]
Other Royalty And Contract Revenues
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Expense of Enforcement, Amount
McKesson
McKesson Corporation [Member]
McKesson Corporation [Member]
Derivative Asset, Statement of Financial Position [Extensible Enumeration]
Derivative Asset, Statement of Financial Position [Extensible Enumeration]
2030
Long-Term Debt, Maturity, Year Four
Goodwill and Intangible Assets
Goodwill and Intangible Assets Disclosure [Text Block]
Use of Estimates
Use of Estimates, Policy [Policy Text Block]
Schedule of Gross Carrying Amount of Goodwill
Schedule of Goodwill [Table Text Block]
Trading Arrangement:
Trading Arrangement [Axis]
Income taxes payable
Increase (Decrease) in Income Taxes Payable
Total Shareholder Return Amount
Total Shareholder Return Amount
Loss Contingencies [Line Items]
Loss Contingencies [Line Items]
Gross Amounts Offset in the Consolidated Balance Sheet
Derivative Asset, Subject to Master Netting Arrangement, Liability Offset
Insider Trading Arrangements [Line Items]
Security Exchange Name
Security Exchange Name
2026 (remainder)
Long-Term Debt, Maturity, Remainder of Fiscal Year
Antidilutive Securities, Name [Domain]
Antidilutive Securities, Name [Domain]
Pension Adjustments Prior Service Cost
Pension Adjustments Prior Service Cost [Member]
Operating expenses:
Operating Expenses [Abstract]
Prepaid expenses
Prepaid Expense, Current
Material Terms of Trading Arrangement
Material Terms of Trading Arrangement [Text Block]
Accrued development expenses
Accrued Development Expenses, Current
Accrued Development Expenses, Current
Offsetting Assets [Line Items]
Offsetting Assets [Line Items]
Derivative Financial Instruments
Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Security Not Offset
Proceeds from sale of priority review voucher
Proceeds from Sale of Other Productive Assets
Statement [Line Items]
Statement [Line Items]
Unamortized - debt issuance costs
Unamortized Debt Issuance Expense
Rule 10b5-1 Arrangement Adopted
Rule 10b5-1 Arrangement Adopted [Flag]
Cash and cash equivalents
Cash and Cash Equivalent
Ordinary Shares
Common Stock [Member]
ASD
ASD Specialty Healthcare LLC [Member]
ASD Specialty Healthcare LLC
Estimated Fair Value
Available-for-sale securities
Debt Securities, Available-for-Sale
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Non-NEOs
Non-NEOs [Member]
Net increase (decrease) in cash and cash equivalents
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Consulting and professional services
Accrued Professional Fees, Current